Search

Your search keyword '"Damon R. Reed"' showing total 165 results

Search Constraints

Start Over You searched for: Author "Damon R. Reed" Remove constraint Author: "Damon R. Reed" Database OpenAIRE Remove constraint Database: OpenAIRE
165 results on '"Damon R. Reed"'

Search Results

1. Randomized Phase III Trial of Ganitumab With Interval-Compressed Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children's Oncology Group

Catalog

Books, media, physical & digital resources

5. Bad to the Bone: Emerging Approaches to Aggressive Bone Sarcomas

6. AI-Radiomics Can Improve Inclusion Criteria and Clinical Trial Performance

7. Supplementary Table 7 from Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab

8. Data from Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab

9. Supplementary Table 3 from Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab

10. Supplementary Table 5 from Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab

11. Supplementary Figure 1 from Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab

12. Supplementary Table 6 from Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab

13. Supplementary Table 2 from Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab

14. Supplemental Legend from Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab

15. Supplementary Table 1 from Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab

16. Supplementary Table 4 from Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab

17. Anti-PD-1 therapy in advanced sarcomas: is cutaneous primary site a stronger predictor of response than histologic subtype?

18. Joint Adult and Pediatric Working Group as a Successful Platform to Strengthen Adolescent and Young Adult (AYA) Clinical Trial Collaboration: A Report from the NCTN/SARC AYA Clinical Trials Sarcoma Working Group

19. Feasibility of an Evolutionary Tumor Board for Generating Novel Personalized Therapeutic Strategies

20. Trends in Overall Survival among Patients Treated for Sarcoma at a Large Tertiary Cancer Center between 1986 and 2014

21. The CMG Helicase and Cancer: A Tumor ‘Engine’ and Weakness with Missing Mutations

22. Retrospective observational studies in ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society (CTOS) community of experts on the minimum requirements for the evaluation of activity of systemic treatments

23. Abstract 276: Delineating the role of vesicular glutamate transporter SLC17A7 in osteosarcoma

24. Deep-learning and MR images to target hypoxic habitats with evofosfamide in preclinical models of sarcoma

25. Communication and ethical considerations for fertility preservation for patients with childhood, adolescent, and young adult cancer

26. Identified Enrollment Challenges of Adolescent and Young Adult Patients on the Nonchemotherapy Arm of Children's Oncology Group Study ARST1321

27. Chemotherapy improves distant control in localized high-grade soft tissue sarcoma of the extremity/trunk

28. An evolutionary framework for treating pediatric sarcomas

29. Exploring patient and provider perspectives on the intersection between fertility, genetics, and family building

31. Phase III Trial Adding Vincristine-Topotecan-Cyclophosphamide to the Initial Treatment of Patients With Nonmetastatic Ewing Sarcoma: A Children's Oncology Group Report

32. Reply to J.-G. Wang et al

33. Outcome of patients with relapsed or progressive Ewing sarcoma enrolled on cooperative group phase 2 clinical trials: A report from the Children's Oncology Group

34. Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group

35. Overall survival and histology‐specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma

36. Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma

37. Provider perceptions’ of a patient navigator for adolescents and young adults with cancer

38. Cannabis consumption in young adults with cancer: descriptive study

39. Clinical Trial Availability by Location for 1000 Simulated AYA Patients

40. Charting a path for prioritization of novel agents for clinical trials in osteosarcoma: A report from the Children's Oncology Group New Agents for Osteosarcoma Task Force

41. Innovative Approaches in the Battle Against Cancer Recurrence: Novel Strategies to Combat Dormant Disseminated Tumor Cells

42. Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities

43. Imaging-based patient inclusion model improves clinical trial performance

44. Phase II trial of gemcitabine and nab-paclitaxel for recurrent osteosarcoma: A report from the National Pediatric Cancer Foundation

45. Long-term outcomes in patients with localized Ewing sarcoma treated with interval-compressed chemotherapy: A long-term follow-up report from Children’s Oncology Group study AEWS0031

46. Targeting hypoxic habitats with hypoxia pro-drug evofosfamide in preclinical models of sarcoma

47. A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment-Refractory Liposarcoma: Results from the SARC024 Study

48. Relapsed Osteosarcoma Trial Concepts to Match the Complexity of the Disease

49. Phase II trial of gemcitabine and nab‐paclitaxel in patients with recurrent Ewing sarcoma: A report from the National Pediatric Cancer Foundation

50. Relapsed Osteosarcoma Trial Concepts to Match the Complexity of the Disease